CD8A and breast carcinoma: It has been reported that TAMs promote the resistance of breast cancer cells to paclitaxel by inhibiting the activation of CD8 + T lymphocytes [42], and TAMs can also promote the chemoresistance of colorectal cells by secreting IL-6 [43].